Impact of renal failure on metabolic bone parameters in a vitamin D-deficient patient cohort

Clinical Nephrology

Volumn 75, Issue 5, 2011, Pages 403-409

  Reinhardt, W ^a,b   Dolff, S ^b   John, P ^a   Kribben, A ^b   Witzke, O ^b  

^a Endocrine Outpatient Clinic and Dialysis Center Herne   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adynamic bone disease; Bone specific alkaline phosphatase; Metabolic bone parameters; Renal failure

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; PARATHYROID HORMONE; ALKALINE PHOSPHATASE; PHOSPHORUS;

ADULT; AGED; ARTICLE; BONE METABOLISM; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; VITAMIN D DEFICIENCY; BLOOD; BONE; COHORT ANALYSIS; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALKALINE PHOSPHATASE; BONE AND BONES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; VITAMIN D DEFICIENCY;

EID: 79958707750     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75403     Document Type: Article

References (24)

1. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16: 2205-2215.
2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams L A, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-38.
3. KDIGO. clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009; 113 (Suppl): 1-130.
4. Frazao JM, Martins P. Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens. 2009; 18: 303-307.
5. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008; 73: 1345-1354.
6. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008; 19: 1827-1835.
7. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003; 41: 997-1007.
8. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999; 56: 1084-1093.
9. Urena P, de Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999; 55: 2141-2156.
10. K/DOQI. clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl): 1-201.
11. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008; 73: 771-777.
12. Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 - 5. Clin Nephrol. 2008; 70: 296-305.
13. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML et al. Mineral metabolism parameters throughout chronic kidney disease stages 1- 5 - achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007; 22: 1171-1176.
14. Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant. 2002; 17: 1419-1425.
15. Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2009; 4: 186-194.
16. Scharla SH, Scheidt-Nave C, Leidig G, Woitge H, Wuster C, Seibel MJ et al. Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based study. Exp Clin Endocrinol Diabetes. 1996; 104: 289-292.
17. Hintzpeter B, Mensink GB, Thierfelder W, Muller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr. 2008; 62: 1079-1089.
18. Carter JL, O'Riordan SE, Eaglestone GL, Delaney MP, Lamb EJ. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study. Nephrol Dial Transplant. 2008; 23: 3554-3565.
19. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P et al. VitaminD levels and patient outcome in chronic kidney disease. Kidney Int. 2009; 75: 88-95.
20. Couttenye MM, D'Haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPDpopulation. Nephrol Dial Transplant. 1997; 12: 2144-2150.
21. CoenG, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998; 13: 2294-2302.
22. Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003; 18: 1159-1166.
23. Tomiyama C, Carvalho AB, Higa A, Jorgetti V, Draibe SA, Canziani ME. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res. 2010; 25: 499-504.
24. Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010; 5: 1268-1276.